Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121514 | 0.89 | TRPV1 (0.35) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL12135334 | 0.88 | ROCK2 (0.38) | PTGS2 | |
| SCHEMBL13206412 | 0.87 | PTGS2 (0.34) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL12136649 | 0.85 | PTGS2 (0.42) | PTGS2MTNR1AMTNR1BTDP1L3MBTL1 | |
| SCHEMBL13199789 | 0.85 | MTNR1A (0.41) | PTGS2MTNR1AMTNR1BTDP1L3MBTL1 | |
| SCHEMBL13206420 | 0.84 | PTGS2 (0.39) | PTGS2MTNR1AMTNR1BTDP1L3MBTL1 | |
| SCHEMBL10144537 | 0.83 | PTGS2 (0.43) | PTGS2MTNR1AMTNR1BTDP1L3MBTL1 | |
| SCHEMBL12136650 | 0.82 | MTNR1A (0.37) | PTGS2MTNR1AMTNR1BTDP1L3MBTL1 | |
| SCHEMBL10144627 | 0.82 | MTNR1A (0.33) | PTGS2MTNR1AMTNR1BTDP1L3MBTL1 | |
| SCHEMBL10144533 | 0.81 | MTNR1A (0.39) | PTGS2MTNR1AMTNR1BTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303978-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOCHEMICAL, LLC (US) | 2012-02-09 | — | — | US | disclosed |
| US-8062653-B2 | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | BEZWADA BIOMEDICAL, LLC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209469-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | PTGS2 59/4885MTNR1A 508/4885MTNR1B 1095/4885 |
| US-20120035259-A1 | Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers | NOS2, NOS1, NOS3 | PTGS2 59/4885MTNR1A 508/4885MTNR1B 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.